Gilead Upgraded to Buy as Amgen Holds Steady, ORIC Earns Analyst Confidence

Analysts have recalibrated their views on three prominent biopharmaceutical companies following recent corporate updates and pipeline developments. Gilead Sciences (GILD) emerged as a top pick after receiving a Buy rating from multiple firms, driven by strong cash flow generation and the continued commercial success of its antiviral portfolio, including ongoing international demand for its HIV and hepatitis B treatments. The stock now trades at a forward P/E of 11.2, below the sector median, signaling undervaluation potential. Amgen (AMGN) was maintained at a Hold rating despite positive Phase 3 trial results for its investigational JAK inhibitor in autoimmune conditions. The decision reflects cautious optimism, with analysts citing near-term revenue stagnation from legacy products and increased competition in the anemia and osteoporosis markets. While the company reported adjusted EPS of $7.12 for Q4 2025, up 5% year-over-year, its growth trajectory remains constrained by patent expirations on key drugs. Oric Pharmaceuticals (ORIC) saw a notable shift in sentiment, with a consensus 'Vote of Confidence' rating based on robust Phase 2 data for its investigational cancer therapy targeting solid tumors. The company’s lead candidate demonstrated a 42% objective response rate in a subset of patients with advanced colorectal cancer, prompting analysts to reassess its long-term value. ORIC’s market cap stands at $14.3 billion, with over $680 million in cash reserves as of December 2025, supporting ongoing clinical trials. The revised ratings are expected to influence portfolio allocations among healthcare-focused funds and institutional investors. GILD and ORIC are likely to see increased analyst coverage and potential inflows, while AMGN may face continued scrutiny on its innovation pipeline. The moves highlight the sector’s ongoing focus on sustainable growth, R&D productivity, and pricing power in a challenging macro environment.